<DOC>
	<DOCNO>NCT01424397</DOCNO>
	<brief_summary>This study design look affect SB-705498 allergic rhinitis symptom induce allergen chamber challenge .</brief_summary>
	<brief_title>Intranasal SB-705498 Allergic Rhinitis ( AR ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>1 . Diagnosis AR , determine presence rhinitis symptom last several month per year , 1 year attribute allergy , infection nasal abnormality . 2 . TNSS score &gt; =4 follow screen allergen challenge chamber . 3 . Positive skin prick test seasonal pollen 4 . Positive RAST seasonal pollen 5 . Healthy determine responsible physician exception mild asthma AR 6 . Male female 18 65 year age inclusive . 7 . A female subject eligible participate : Nonchildbearing potential define premenopausal female \documented tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 147 pmol/L ) confirmatory ] . Childbearing potential agrees use one contraception method list instructed . Female subject must agree use contraception 84 day postlast treatment administration . 8 . Male subject female partner childbearing potential must agree use one contraception instruct . This must follow time first dose study medication 84 day postlast treatment administration . 9 . Body weight ≥ 50 kg ( male ) ≥45kg ( female ) BMI within range 19 29.9 kg/m2 ( inclusive ) . 10 . Screening prechallenge FEV1 great equal 80 % baseline FEV1/FVC great equal 70 % predict value . 11 . Capable give write informed consent . 12 . Average QTcB , &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . 13 . AST ALT &lt; 2xULN ; alkaline phosphatase bilirubin less equal 1.5xULN 1 . Nasal abnormality likely affect outcome study , 2 . History frequent nosebleed . 3 . Respiratory disease mild asthma 4 . A positive prestudy Hepatitis B Hepatitis C result within 3 month screen 5 . Current chronic history liver disease , know hepatic biliary abnormality 6 . Positive prestudy drug/alcohol/smoking screen . 7 . A positive test HIV antibody . 8 . History regular alcohol consumption within 6 month study define : • An average weekly intake &gt; 14 drink male &gt; 7 drink female . 9 . The subject participate clinical trial receive investigational product within 30 day , 5 halflives twice duration biological effect investigational product prior D1 . 10 . Exposure four new chemical entity within 12 month prior D1 . 11 . Use prescription nonprescription drug , include vitamin , herbal dietary supplement within 7 day prior first dose study medication . 12 . History sensitivity study medication , component 13 . Where participation study would result donation blood blood product excess 500 mL within 56 day period . 14 . Pregnant female determine positive serum urine hCG test screen prior dosing . 15 . Lactating female . 16 . Subject mentally legally incapacitate . 17 . Urine cotinine level indicative smoking</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>